Abstract: A method of configuring a signal transducer of a foldable UE includes: providing a first panel comprising a first conductor configured to provide a first portion of the signal transducer; providing a second panel comprising a second conductor configured to provide a second portion of the signal transducer; providing a hinge connected to the first panel and the second panel and configured to allow the first panel to rotate relative to the second panel about a pivot axis of the hinge, the hinge comprising a third conductor configured to provide a third portion of the signal transducer, the third conductor electrically coupling the first conductor to the second conductor; providing a fourth conductor that is physically separate from the first conductor, the second conductor, and the third conductor; and selectively causing the fourth conductor to provide a fourth portion of the signal transducer.

Abstract: A three-phase resonant converter includes a three-phase transformer, an input bridge arm assembly, an output bridge arm assembly, and a control unit. The input bridge arm assembly has three input switch arms, and each input switch arm has an upper switch and a lower switch. The output bridge arm assembly has three output synchronous rectification switch arms respectively coupled to the three secondary-side windings. Each output synchronous rectification switch arm has an upper rectification switch and a lower rectification switch. The control of each output synchronous rectification switch arm is corresponding to the control of each input switch arm. The control unit controls the upper rectification switch or the lower rectification switch to be turned on with a leading phase angle to the corresponding upper switch or the lower switch so as to maintain an output voltage of the resonant converter to be higher than a voltage threshold.

Abstract: A kit for detecting urothelial carcinoma is provided. The kit includes at least one primer or probe for detecting one or more miRNAs, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof. A method for detecting urothelial carcinoma is also provided. The method includes detecting the expression level(s) of one or more miRNAs in a sample of a subject, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof.

Abstract: A method for estimating a risk for a subject suffering from an urothelial carcinoma is provided, including measuring an expression level of at least one miRNA in a sample of the subject, and the miRNA is selected from miR-1274, miR-19a, miR-30, and miR-708; and comparing the expression level of the same miRNA in the sample to that of a control for estimating whether the subject has the risk of suffering from the urothelial carcinoma or not. A kit for estimating a risk for a subject suffering from an urothelial carcinoma is also provided, including at least one reagent for detecting an expression level of at least one miRNA as above mentioned in a sample of the subject.

Abstract: A kit for detecting urothelial carcinoma is provided. The kit includes at least one primer or probe for detecting one or more miRNAs, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof. A method for detecting urothelial carcinoma is also provided. The method includes detecting the expression level(s) of one or more miRNAs in a sample of a subject, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof.

Abstract: A medical magnetic pellet is provided. The magnetic pellet includes a porous matrix and magnetic powder distributed in the porous matrix. Moreover, an active substance also can be added to be distributed in the matrix. The porous matrix of the magnetic pellet can carry active substances or absorb target substances.

Abstract: A vegetarian pore-sealing capsule is provided. The pore-sealing capsule may release active substances in a gastrointestinal tract, including stomach, duodenum, jejunum, ileum and colon, under control. The pore-sealing capsule includes a capsule shell having one or more pores and a pore-sealing material for sealing at least one of the pores. When the pore-sealing capsule is located at a destination inside the gastrointestinal tract, the pore-sealing material will leave the pores.

Abstract: Disclosed herein is an active pellet. The active pellet includes a body and interspaces. The body includes an active ingredient ranging from 50 to 100 wt %, free of chemical additives.

Abstract: Disclosed herein is an active pellet. The active pellet includes a body and interspaces. The body includes an active ingredient ranging from 50 to 100 wt %, free of chemical additives.